文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2022 版

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

机构信息

Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Yale Cancer Center/Smilow Cancer Hospital.

出版信息

J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.


DOI:10.6004/jnccn.2022.0030
PMID:35714673
Abstract

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

摘要

对于非浸润性或浸润性乳腺癌患者,治疗选择复杂多样。这些 NCCN 乳腺癌临床实践指南包括对原位癌、浸润性乳腺癌、派杰病、叶状肿瘤、炎性乳腺癌患者的临床管理建议,以及妊娠期间乳腺癌的管理建议。本期内容重点介绍了导管原位癌整体管理建议,以及早期浸润性乳腺癌的检查和局部区域管理建议。欲了解 NCCN 乳腺癌指南全文,请访问 NCCN.org。

相似文献

[1]
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2022-6

[2]
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2024-7

[3]
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2018-3

[4]
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

J Natl Compr Canc Netw. 2021-5-1

[5]
Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region.

J Natl Compr Canc Netw. 2010-7

[6]
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

J Natl Compr Canc Netw. 2023-6

[7]
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2020-3

[8]
NCCN: Breast cancer.

Cancer Control. 2001

[9]
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2022-4

[10]
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2016-3

引用本文的文献

[1]
Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study.

World J Surg Oncol. 2025-9-5

[2]
Evaluation of serum alkaline phosphatase and lactate dehydrogenase as predictive biomarkers for the prognosis of male breast cancer.

Sci Rep. 2025-8-27

[3]
Impact of radiation therapy on breast satisfaction and health-related quality of life after breast reconstruction: a multicenter cross-sectional controlled study (Reborn study-02).

Breast Cancer. 2025-8-22

[4]
Efficacy of Saffron ( L.) and Its Constituents on Breast Cancer, a Systematic Review of Preclinical Studies and Potential Therapeutic Mechanisms.

Integr Cancer Ther. 2025

[5]
Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study.

Cancers (Basel). 2025-8-7

[6]
Breast cancer survival rates and determinants in Ethiopia: a systematic review and meta-analysis of longitudinal studies.

BMC Cancer. 2025-8-4

[7]
Multi-omics prediction of axillary treatment response and tumour microenvironment alterations in lymph node-positive luminal breast cancer.

Cell Death Dis. 2025-8-4

[8]
Machine learning-based single-sample molecular classifier for cancer grading.

Front Oncol. 2025-7-16

[9]
PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.

Oncotarget. 2025-7-29

[10]
Exploring personalized neoadjuvant therapy selection strategies in breast cancer: an explainable multi-modal response model.

EClinicalMedicine. 2025-7-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索